The Ripple Effect 2.0: from global health to domestic value
This executive briefing highlights findings from three case studies: the Shingrix shingles vaccine, the JADA System for postpartum haemorrhage and BCG as a treatment for bladder...
Hubs
The Impact of Global Health R&D Hub
Is this the world's best investment? The success of global health R&D over the past 20 years is a resounding one - and yet R&D funding to tackle neglected diseases has fallen since the pandemic. In breakthrough work, we find a staggering return on that investment in terms of societal benefit.
Hub Editors
Dr Céline Aerts
Analyst
making an impact
Global health is the world's best investment
In breakthrough work, we analyse the impact of global health R&D, showing the return on investment in health and economic terms for the first time. We look at the products which have been gamechangers over the last two decades and model the future returns of health innovations which transform the health and economic outlook for vulnerable populations.
PDF of the global reportInteractive report findingsVideo of the report launch$405
returned in societal value for every $1 invested
30%
drop in deaths from poverty-related diseases in last 20 years
The Ripple Effect 2.0: from global health to domestic value
Moving beyond the quantified macro-level economic gains of global health R&D detailed in The Ripple Effect, The Ripple Effect 2.0 measures product-specific health and economic impacts in HICs. We spotlight three case studies: the Shingrix shingles vaccine, the JADA System for postpartum haemorrhage and BCG as a treatment for bladder cancer, that show how innovations developed for LMICs have gone on to help HIC populations, proving that smart, sustained investment pays dividends globally and locally.
Read more
From malaria research to protecting aging populations: AS01 Adjuvant in Shingrix
This case study focuses on the benefits of AS01 adjuvant, initially advanced through malaria research, before being adopted to enhance the effectiveness of GSK’s ‘Shingrix’...
From targeted solution to global maternal health asset: the JADA System
This case study focuses on the benefits of the JADA System – a device designed to stop bleeding by inducing a gentle vacuum in the uterus uterine device – for the rapid control of...
From TB prevention to cancer: the BCG vaccine treating bladder cancer
This case study focuses on the benefits of the BCG vaccine, originally developed from preventing tuberculosis (TB), which is now used as an alternative to chemotherapy in the...
Innovation Spillover Tracker
A tracker of health innovations developed for LMICs that have translated into new applications and benefits in HICs.
Why global health R&D is one of the smartest investments governments can make
Céline Aerts uncovers the wide range of spillover effects that global health R&D produces in high-income countries.
Interactive map
High-income countries benefit from global health R&D
Explore our interactive map to see how investments in global health R&D deliver domestic benefits and cost savings to high-income countries
All resources in this hub
5 min read
The Ripple Effect 2.0: video
Key messages from The Ripple Effect 2.0 which provides quantitative, country-specific proof points showing how innovations originally developed to address health needs in low- and middle-income countries (LMICs) are now improving health outcomes and delivering economic value across the United States, United Kingdom, Japan, and Europe.
10 min read
Why global health R&D is one of the smartest investments governments can make
Céline Aerts uncovers the wide range of spillover effects that global health R&D produces in high-income countries.
10 min read
The Ripple Effect 2.0: from global health to domestic value
This executive briefing highlights findings from three case studies: the Shingrix shingles vaccine, the JADA System for postpartum haemorrhage and BCG as a treatment for bladder cancer. It provides quantitative, country-specific proof points showing how these selected global health innovations improve health outcomes and deliver economic value across the US, UK, Japan and Europe.
5 min read
From malaria research to protecting aging populations: AS01 Adjuvant in Shingrix
This case study focuses on the benefits of AS01 adjuvant, initially advanced through malaria research, before being adopted to enhance the effectiveness of GSK’s ‘Shingrix’ shingles vaccine.
5 min read
From targeted solution to global maternal health asset: the JADA System
This case study focuses on the benefits of the JADA System – a device designed to stop bleeding by inducing a gentle vacuum in the uterus uterine device – for the rapid control of PPH in the USA.
5 min read
From TB prevention to cancer: the BCG vaccine treating bladder cancer
This case study focuses on the benefits of the BCG vaccine, originally developed from preventing tuberculosis (TB), which is now used as an alternative to chemotherapy in the treatment of bladder cancers in high income countries.
30 min read
The ripple effect: how global health R&D delivers for everyone
This report shows how investments in global health R&D deliver significant health and economic progress for HICs as well as LMICs. We examine how much government funding from HICs has gone to global health R&D, how much of it stays within HICs, and the macroeconomic and scientific gains it leads to. We spotlight case studies that show how innovations developed for LMICs have gone on to help HIC populations, proving that smart, sustained investment pays dividends globally and locally.
5 min read
The ripple effect: Video
Key messages from the September 2025 report on the ripple effect of high-income country investment in global health R&D
40 min read
The 2025 Neglected Disease R&D Pipeline review: Time to close the gaps
Amid reduced funding, political uncertainty, and rising infectious disease, this report assesses the health of the neglected diseases (ND) pipeline to empower funders, policymakers, and advocates to prioritize high impact investments. This report delves into a decade of ND pipeline insights to guide future investment strategies.
...
You may also be interested in
Report Library
Browse our full archive of reports. Filter by health area, disease or condition, product, and date. Written by our expert analysts, our reports highlight key messages in the data, make the case for change and offer actionable recommendations.
Disease and condition
Our Health Areas resource gives you an at-a-glance summary of the state of innovation and annual R&D investment by disease and condition. Updated regularly, this is a unique quick reference for the global health community.